CAMBRIDGE, Mass.– Convergent Therapeutics Inc. and NorthStar Medical Radioisotopes said they have expanded their partnership to support late-stage clinical development and future commercialization of Convergent’s lead alpha-emitting radioantibody program, CONV01-α.
Under the expanded agreement, Convergent will establish dedicated drug product manufacturing suites on NorthStar’s Beloit, Wisconsin campus to support late-stage clinical studies and anticipated commercial demand. The companies said the co-location of manufacturing is intended to create an integrated and reliable supply chain for CONV01-α, including access to high-purity Actinium-225 (Ac-225), a critical isotope for alpha-based radiotherapies.
By situating its manufacturing operations at NorthStar’s campus, Convergent aims to reduce supply constraints associated with alpha-emitting radiopharmaceuticals and ensure continuity of production from clinical development through commercial scale.
“The relationship with NorthStar enables us to fully realize the potential of our leading radioantibody program as we demonstrate the advantages of alpha emitters in addressing metastatic castration-resistant prostate cancer (mCRPC) and the significant need for new, safer, and more effective therapies for patients,” said Philip Kantoff, M.D., chief executive officer and co-founder of Convergent. “With secured Ac-225 supply, clinical proof-of-concept, and potential best-in-class efficacy and tolerability, CONV01-α is well-positioned to advance mCRPC treatment. Our strategic investment in manufacturing will support late-stage monotherapy studies of CONV01-α, and additional trials to assess CONV01-α in earlier stages of prostate cancer and in combination with other therapeutics.”
CONV01-α is Convergent’s lead program for mCRPC and anchors a broader pipeline of radiopharmaceuticals designed to leverage the precision and potency of alpha-emitting isotopes. NorthStar recently announced it is producing alpha radioisotopes for therapeutic use at scale, with Convergent identified as a key customer for Ac-225. The companies said reliable access to Ac-225 will further support Convergent’s clinical and commercial ambitions for next-generation alpha-based therapies.
“We are pleased to expand our partnership with Convergent,” said Frank Scholz, president and chief executive officer of NorthStar Medical Radioisotopes, LLC. “This agreement underscores the value of our integrated campus designed to reduce complexity and create a robust, reliable supply chain to deliver patient-ready drugs.”
The expanded partnership builds on a contract manufacturing services agreement announced in August 2024, under which NorthStar agreed to supply Ac-225 for CONV01-α and manufacture the drug product at its contract development and manufacturing facility for clinical trials and related research and development activities.
“Having drug product and Ac-225 supply co-located on the NorthStar campus provides a unique advantage for our supply chain, enabling greater efficiencies, flexibility, and cost savings, as we leverage NorthStar’s extensive track record in radiopharmaceutical manufacturing,” said Caitlyn Harvey, head of manufacturing at Convergent. “Their leadership in producing alpha emitters for radiotherapies ensures critical production capabilities and access to Ac-225 are in place for pivotal studies through commercial launch and beyond.”
